Seres Therapeutics Inc

NASDAQ:MCRB   3:59:58 PM EDT
5.69
+0.32 (+5.96%)
Earnings Announcements

Seres Therapeutics Reports Second Quarter 2022 Financial Results And Provides Business Updates

Published: 08/03/2022 11:19 GMT
Seres Therapeutics Inc (MCRB) - Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates.
Expect to Complete Ser-109 Biologics License Application Filing in Coming Weeks.
Qtrly Net Loss per Share Attributable to Common Stockholders, Basic and Diluted $0.70.
Q2 Earnings per Share View $-0.60 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $3.87 Million
Adjusted EPS is expected to be -$0.47

Next Quarter Revenue Guidance is expected to be $3.87 Million
Next Quarter EPS Guidance is expected to be -$0.44

More details on our Analysts Page.